Earn CME/CE in your profession:

Continuing Education Activity

Esmolol (esmolol hydrochloride) is an intravenous cardioselective beta-1 adrenergic antagonist. Esmolol is used in various settings, including urgent care, perioperatively, and postoperatively. It is indicated in sinus tachycardia, where a rapid rate requires intervention secondary to other comorbidities. Esmolol is FDA-approved for tachycardia and hypertension induced by intubation. It is off-labeled for rate and rhythm control in aortic dissection, acute coronary syndrome, non-ST elevation myocardial infarction, hypertensive emergencies, thyrotoxicosis, refractory ventricular tachycardia, refractory to defibrillation ventricular fibrillation, and to decrease catecholamine response during electroconvulsive therapy. This activity will highlight the mechanism of action, adverse events, pharmacology, monitoring, and relevant interactions of esmolol, pertinent for interprofessional team members in treating patients with tachycardia and other related conditions where esmolol will provide a benefit.


  • Identify the mechanism of action of esmolol.
  • Summarize the indications for using esmolol.
  • Review the potential adverse effects of esmolol.
  • Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients when using esmolol.


Esmolol (esmolol hydrochloride) is an intravenous cardioselective beta-1 adrenergic antagonist.[1] In the contemporary era, esmolol has the following indications:

  • Esmolol is FDA-approved for short-term use in controlling supraventricular tachycardia, such as a rapid ventricular rate in patients with atrial fibrillation or atrial flutter. It is also a useful emergency drug for focal atrial tachycardia, especially in patients with active bronchospasm.[2] 
  • Esmolol has also been reported to be a safe and effective drug for perioperative blood pressure control, owing to its short half-life.[3] 
  • It is also indicated in sinus tachycardia, where a rapid rate requires emergent intervention, especially in acute coronary syndrome.[4]
  • Esmolol is also recommended for treating tachyarrhythmia in critically ill patients and hypertension induced by intubation.[5] 
  • Off-labeled, it is used in aortic dissection, acute coronary syndrome, non-ST elevation myocardial infarction, hypertensive emergencies, thyrotoxicosis, refractory ventricular tachycardia, refractory to defibrillation ventricular fibrillation.[6] 
  • It is also used to decrease catecholamine response during electroconvulsive therapy.[7]
  • According to a recent study, esmolol may improve survival for patients with refractory ventricular fibrillation (RVF) in prehospital settings.[8]
  • According to 2019 AHA/ACC/HRS (American College of Cardiology/American Heart Association/ Heart Rhythm Society) guidelines, intravenous beta-blockers such as esmolol are recommended to slow a rapid ventricular response in patients with AF who do not have heart failure, hemodynamic instability, or bronchospasm.[9]

Mechanism of Action

Esmolol is a short-acting, cardio-selective beta-blocker, a class II antiarrhythmic agent that is a competitive antagonist of the beta-1-adrenergic receptors primarily in the myocytes.[10] By blocking the adrenergic activity of epinephrine and norepinephrine, it decreases contractility(negative inotropic effect), heart rate(negative chronotropic effect), and conduction.[11] Esmolol increases atrioventricular refractory time, decreases oxygen demand of the myocardium, and decreases atrioventricular conduction(negative dromotropic effect). A minor beta-2-adrenergic blockade has been reported with high intravenous infusion doses. Esmolol does not have any membrane-stabilizing activity or alpha-adrenergic blockade.


Absorption: Esmolol is rapidly absorbed, the onset of action is within 60 seconds, and it maintains a steady state within 5 minutes of initiation of infusion.[12] A steady state is achieved at the 2-minute if a loading dose is administered. The drug has a 9-minute half-life and rapid renal clearance.

Distribution: Esmolol has plasma protein binding of 55%.The mean apparent volume of distribution is approximately 0.33 to 0.53 L/kg.[13]

Metabolism: Fast metabolism translates into the rapid decrease of pharmacological effect (within 10 to 30 minutes) once the infusion is discontinued, making esmolol safer when titrated appropriately.[14] Hydrolysis by the esterases in erythrocytes metabolizes esmolol to an acid metabolite and methanol, thus eliminating the need for dose adjustments in renal or hepatic dysfunction.[13]

Excretion: The metabolite has a half-life of 3.7 hours and is excreted via urine. Esmolol has a higher clearance (281 mL/kg/min) in infants than in adults and children.[12]


Esmolol is administered intravenously, preferably through central venous access; however, it can also be infused peripherally. FDA approval was based on adult subjects; pediatric dosages have been experimental and are not approved by the FDA.

Perioperative and Postoperative Tachycardia and Hypertension

Two Methods

  • A 1000 mcg/kg bolus over 30 seconds, followed by 150 mcg/kg per minute infusion, with a max dose of 300 mcg/kg per minute.
  • A bolus of 500 mcg/kg over 1 minute, followed by 50 mcg/kg per minute infusion for 4 minutes. If the desired effect is not reached, it may increase in 50 mcg/kg per minute increments until the max dose of 300 mcg/kg per minute.[15]

Supraventricular Tachycardia and Sinus Tachycardia

  • Bolus loading dose of 500 mcg/kg over 1 minute, followed by 50 mcg/kg/min infusion for 4 minutes. If the desired effect is not reached, it may increase in 50 mcg/kg per minute increments until the max dose of 200 mcg/kg per minute. For rapid efficacy, follow the initial loading dose and infusion of 50 mcg/kg per minute by a second 500 mcg/kg bolus over 1 minute and increase drip to 100 mcg/kg per minute for 4 minutes.[16] 

Off-label Use

Hypertensive Emergency

  • Loading dose of 500 to 1000 mcg/kg over 1 minute (can be repeated once), followed by infusion of 50 mcg/kg per minute until the max dose of 200 mcg/kg per minute is achieved.[17][18]

Aortic Dissection

  • Loading dose of 500 mcg/kg over 2 to 5 minutes, followed by infusion of 10 to 20 mcg/kg per minute.[19]

Acute Coronary Syndrome

  • Loading dose of 500 mcg/kg over 1 minute, followed by 50 mcg/kg per minute infusion titrated every 5 to 15 minutes until the max dose of 300 mcg/kg per minute.[20]

Electroconvulsive Therapy

  • Loading dose of 1000 mcg/kg over 1 minute before administration of anesthesia.[21]


  • 50 to 100 mcg/kg per minute

Intubation Cholinergic Response

  • Loading dose of 1000 to 2000 mcg/kg administered 1.5 to 3 min before endotracheal intubation.

Ventricular Tachycardia/Ventricular Fibrillation

  • Loading dose of 500 mcg/kg bolus, followed by 50 mcg/kg per minute

Esmolol should be used short-term, with a maintenance dose infusion not exceeding 48 hours. Most patients on esmolol infusions will be transitioned to other long-term agents. Once the effects of esmolol are no longer needed, it should not be discontinued suddenly.[4] New medication should be initiated, followed by titrating esmolol down by 50% and reassessing hemodynamic stability. If the patient is stable, continue to slowly titrate the esmolol down while titrating the new agent until the desired heart rate and blood pressure are achieved. Peripheral extravasations can cause thrombophlebitis. If the extravasation occurs, the infusion should be stopped, the line should be gently aspirated, and the limb should be elevated.

Use in Specific Patient Populations

Patients with Hepatic  Impairment: Esmolol does not require dosage adjustment for hepatic impairment.[22]

Patients with Renal Impairment: Esmolol does not require dosage adjustment for renal impairment.[23]

Pregnancy Considerations: Esmolol is a category C drug in pregnancy. During trials in third-trimester pregnancy and labor, Esmolol has been shown to cause fetal bradycardia, which persisted after the drug infusion was discontinued.[24]

Breastfeeding Considerations: Esmolol has 55% plasma protein binding, < 1% renal excretion, and a short half-life of < 10 minutes; hence, infants have no risk of accumulation. As there is no conclusive data regarding milk excretion, however, it should not be used in breastfeeding mothers due to the serious potential for adverse effects.[13][25]

Adverse Effects

  • The most common adverse reaction with esmolol is a hemodynamic compromise, which happens to over 10% of all patients.[26]
  • The risk of asymptomatic (25%) and symptomatic (12%) hypotension occurs at all doses, but the risk is dose-dependent.[27] Hypotension in Esmolol patients often appears once doses reach 150 mcg/kg per minute. In clinical trials, Esmolol-induced hypotension was usually corrected by titrating down or discontinuing the infusion.
  • Patients also experienced dizziness (3%), peripheral ischemia (1%), and infusion site reaction (8%), such as blistering/necrosis/thrombophlebitis.[16] 
  • Rare side effects (less than 1% of patients without comorbidities) included bradycardia, decompensated heart failure, cardiac arrest, and heart block.[28]
  • Esmolol did not show any significant laboratory abnormalities, and patients tolerated the drug well while being infused for up to 24 hours. However, some cases of hyperkalemia with esmolol use have been reported. Therefore, electrolyte levels should be monitored for hyperkalemia in patients with renal disease.[29]
  • Hypoglycemic-induced tachycardia is often not present with the use of Esmolol, like other beta-blockers. Patients with diabetes who are on Esmolol should be closely monitored. Esmolol has also been reported to exacerbate coronary vasospasms, such as Prinzmetal’s Angina.[30]
  • In a setting of a patient with pheochromocytoma, esmolol should be given with an alpha-blocker not to have beta-blockage without opposed alpha. Patients with a history of hyperthyroidism should be closely monitored after discontinuation of esmolol may exacerbate hyperthyroidism. Esmolol may also aggravate arterial insufficiency in patients with a history of significant peripheral vascular disease.[31]
  • As the excipient contains methanol, esmolol should be avoided in patients with methanol poisoning.[12]

Drug-Drug Interactions

Numerous drug-drug interactions exist with esmolol, the most significant being:

  • Digoxin: 10% to 20% increase in digoxin levels, with may aggravate slow AV conduction and heart rate
  • Anticholinesterases: Prolonged neuromuscular junction blockage and recovery time
  • Calcium channel blockers: Decreases myocardial contractility and may trigger cardiac arrest.
  • Vasoconstrictor and inotropic agents: Esmolol should not be used to control heart rate elevation in patients who receive peripheral vascular constrictive agents such as epinephrine, norepinephrine, and dopamine.[32][33]


Esmolol is contraindicated in patients with sinus bradycardia, sick sinus syndrome, atrioventricular heart block, heart failure, cardiogenic shock, pulmonary hypertension, and a history of hypersensitivity reactions to esmolol. In addition, Esmolol and calcium channel blockers should not be given together, as this may exacerbate hypotension and bradycardia.

Patients with first-degree heart block and nodal dysfunctions are at an increased risk of progressive heart block, bradycardia, and AV dissociation. Patients with preexisting heart failure are at greater risk of decompensated heart failure and cardiogenic shock.[34] 

Clinicians should be cautious when using beta-blocker, such as esmolol, in patients with airway diseases such as asthma and COPD; even though the beta-2 receptor's effects are minimal, some risks may exist at higher doses.[35]


Esmolol is an ultra-fast-acting medication that can quickly alter heart rate and pressure. While the patient is on esmolol, it is recommended that they have continuous blood pressure monitoring, heart rate, mean arterial pressure, and, if possible, EKG.[36] An arterial line will provide the best method of continuous blood pressure monitoring, which is beneficial in use with esmolol.

The peripheral intravenous (IV) site should be checked regularly for any signs or symptoms of infiltration and extravasation.

As mentioned above, in patients with comorbidities, appropriate blood levels should be monitored, such as glucose (diabetes), thyroid levels (hyperthyroid), potassium (renal insufficiency), and peripheral pulses (peripheral vascular disease).[37]

The CHA2DS2-VASc score should be measured for risk stratification of a thromboembolic event and decision regarding anticoagulation according to AHA/ACC guidelines.[9]


An overdose of esmolol can result in a myriad of symptoms and effects. Cardiac signs of toxicity include but are not limited to bradycardia, AV block of any degree, complete AV dissociation, decrease contractility, cardiogenic shock, asystole, and pulseless electrical activity.[38] Neurologic signs of toxicity include but are not limited to respiratory irregularities, seizures, coma, and psychiatric symptomatology.[39] Other symptoms of toxicity may include bronchospasms, gastrointestinal mesenteric ischemia, and peripheral cyanosis.

Since Esmolol has a very short half-life (9 minutes), toxicity should be treated by discontinuing the esmolol infusion. Acute toxicity is often self-limited and is treated supportively. Toxicity that results in bradycardia should be treated by atropine, pacing, and other anticholinergic agents. Cardiogenic shock can be treated with inotropic agents like dobutamine, dopamine, and isoproterenol. Bronchospasms, even though rare, should be treated with a beta-2 agonist, such as albuterol.[40] 

The Advanced Cardiac Life Support protocols should treat pulseless electrical activity and cardiac arrest. As with other beta-blocker overdoses, calcium chloride can be given to mitigate the effects of esmolol while it is being metabolized. High-dose insulin euglycaemic therapy and veno-arterial extracorporeal membrane oxygenation are associated with a reduction in mortality.[41]

Enhancing Healthcare Team Outcomes

Healthcare professionals, including those in the MICU and CCU who administer esmolol, should be familiar with its adverse effects. Esmolol is an ultra-fast-acting medication that can quickly control heart rate and pressure. Therefore, while the patient is on esmolol, it is recommended that nursing staff continuously monitor patients for blood pressure, heart rate, mean arterial pressure, and, if possible, EKG. An arterial line will provide the best method of continuous blood pressure monitoring, which is beneficial in use with esmolol. When given peripherally, the intravenous (IV) site should be checked regularly to ensure that it did not infiltrate and extravasate. As mentioned above, in patients with comorbidities, appropriate blood levels should be monitored, such as glucose (diabetes), thyroid levels (hyperthyroid), potassium (renal insufficiency), and peripheral pulses (peripheral vascular disease). The pharmacist should perform medication reconciliation and inform the prescriber of any concerns.

Given the pharmacodynamics of esmolol, it is advisable to use an interprofessional team approach to using the drug. This interprofessional team will include clinicians (MDs, DOs, NPs, and PAs), specialists including EP consult service, nurses, and pharmacists, all coordinating their activities and communicating openly so all team members are operating from the same information and can intervene or report the need for intervention and achieve optimal patient outcomes related to esmolol therapy. According to the 2016 ESC (European Society of Cardiology), managing patients with atrial fibrillation (AF) requires coordination from an interprofessional team consisting of specialists, stroke physicians, cardiologists, clinicians, AF surgeons, allied healthcare professionals, patients, and family members and integrated care has the potential to enhance patient outcomes.[42] [Level 5]



Intisar Ahmed


7/30/2023 2:05:23 AM



O'Flaherty D, Esmolol. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 1993 Jul;     [PubMed PMID: 8104725]


Das G,Tschida V,Gray R,Dhurandhar R,Lester R,McGrew F,Askenazi J,Kaplan K,Emanuele M,Turlapaty P, Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents. Journal of clinical pharmacology. 1988 Aug;     [PubMed PMID: 2905710]


Gray RJ,Bateman TM,Czer LS,Conklin CM,Matloff JM, Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. Journal of the American College of Cardiology. 1985 Jun     [PubMed PMID: 2860148]


Garnock-Jones KP, Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs. 2012 Jan 1     [PubMed PMID: 22191799]


Gassanov N,Er F, [The Role of Ultrarapid Acting Betablocker Esmolol and Landiolol in Critically Ill Patients]. Deutsche medizinische Wochenschrift (1946). 2019 Sep     [PubMed PMID: 31514219]


Sung RJ,Blanski L,Kirshenbaum J,MacCosbe P,Turlapaty P,Laddu AR, Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia. Journal of clinical pharmacology. 1986 Mar     [PubMed PMID: 2870082]


Aydogan MS,Yücel A,Begec Z,Colak YZ,Durmus M, The hemodynamic effects of dexmedetomidine and esmolol in electroconvulsive therapy: a retrospective comparison. The journal of ECT. 2013 Dec;     [PubMed PMID: 23774056]

Level 2 (mid-level) evidence


Patrick C,Crowe RP,Ward B,Mohammed A,Keene KR,Dickson R, Feasibility of prehospital esmolol for refractory ventricular fibrillation. Journal of the American College of Emergency Physicians open. 2022 Apr     [PubMed PMID: 35425942]

Level 2 (mid-level) evidence


January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019 Jul 9:140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28     [PubMed PMID: 30686041]

Level 1 (high-level) evidence


Three generations of β-blockers: history, class differences and clinical applicability., do Vale GT,Ceron CS,Gonzaga NA,Simplicio JA,Padovan JC,, Current hypertension reviews, 2018 Sep 17     [PubMed PMID: 30227820]


Agrios J,Kaladaridou A,Bramos D,Skaltsiotes E,Pamboucas C,Papadopoulou E,Toumanidis S,Moulopoulos S, The acute effects of esmolol on left ventricular hemodynamic, rotational mechanics and strain in intact and infracted myocardium: An experimental study. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 2021 Jul-Aug     [PubMed PMID: 32800920]


Wiest DB,Haney JS, Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clinical pharmacokinetics. 2012 Jun 1     [PubMed PMID: 22515557]


Esmolol Drugs and Lactation Database (LactMed). 2006;     [PubMed PMID: 30000207]


Covinsky JO, Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life. Drug intelligence & clinical pharmacy. 1987 Apr     [PubMed PMID: 2882993]


Poveda-Jaramillo R,Monaco F,Zangrillo A,Landoni G, Ultra-Short-Acting β-Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill Patients. Journal of cardiothoracic and vascular anesthesia. 2018 Jun;     [PubMed PMID: 29398384]


Wiest D, Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clinical pharmacokinetics. 1995 Mar;     [PubMed PMID: 7758250]


Rhoney D,Peacock WF, Intravenous therapy for hypertensive emergencies, part 2. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2009 Aug 15;     [PubMed PMID: 19667001]


Esmolol LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012     [PubMed PMID: 31644101]


Krenz JR,O'Brien ME,Lee J,Hayes BD, Evaluation of esmolol for heart rate control in patients with acute aortic dissection. The American journal of emergency medicine. 2021 Jun     [PubMed PMID: 32354528]


Kloner RA,Kirshenbaum J,Lange R,Antman EM,Braunwald E, Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia. The American journal of cardiology. 1985 Oct 23     [PubMed PMID: 2864848]


Howie MB,Hiestand DC,Zvara DA,Kim PY,McSweeney TD,Coffman JA, Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation. Anesthesia and analgesia. 1992 Nov;     [PubMed PMID: 1358003]


Buchi KN,Rollins DE,Tolman KG,Achari R,Drissel D,Hulse JD, Pharmacokinetics of esmolol in hepatic disease. Journal of clinical pharmacology. 1987 Nov     [PubMed PMID: 3323260]


Flaherty JF,Wong B,La Follette G,Warnock DG,Hulse JD,Gambertoglio JG, Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clinical pharmacology and therapeutics. 1989 Mar     [PubMed PMID: 2563962]


Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European heart journal. 2018 Sep 7:39(34):3165-3241. doi: 10.1093/eurheartj/ehy340. Epub     [PubMed PMID: 30165544]


Ostman PL,Chestnut DH,Robillard JE,Weiner CP,Hdez MJ, Transplacental passage and hemodynamic effects of esmolol in the gravid ewe. Anesthesiology. 1988 Nov;     [PubMed PMID: 2903702]


Yu SK,Tait G,Karkouti K,Wijeysundera D,McCluskey S,Beattie WS, The safety of perioperative esmolol: a systematic review and meta-analysis of randomized controlled trials. Anesthesia and analgesia. 2011 Feb     [PubMed PMID: 21127279]

Level 1 (high-level) evidence


Byrd RC,Sung RJ,Marks J,Parmley WW, Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. Journal of the American College of Cardiology. 1984 Feb;     [PubMed PMID: 6141193]


Beta Adrenergic Blocking Agents LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012     [PubMed PMID: 31643457]


Cork RC,Kramer TH,Dreischmeier B,Behr S,DiNardo JA, The effect of esmolol given during cardiopulmonary bypass. Anesthesia and analgesia. 1995 Jan     [PubMed PMID: 7802296]


Pham D,Addison D,Kayani W,Misra A,Jneid H,Resar J,Lakkis N,Alam M, Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis. Emergency medicine journal : EMJ. 2018 Sep     [PubMed PMID: 29921621]

Level 1 (high-level) evidence


Askenazi J,MacCosbe PE,Hoff J,Turlapaty P,Hua TA,Laddu A, Hemodynamic effects of esmolol, an ultrashort-acting beta blocker. Journal of clinical pharmacology. 1987 Aug     [PubMed PMID: 2888793]


Lowenthal DT,Porter RS,Achari R,Turlapaty P,Laddu AR,Matier WL, Esmolol-digoxin drug interaction. Journal of clinical pharmacology. 1987 Aug;     [PubMed PMID: 2888792]


Kim KS,Kim KH,Shin WJ,Yoo HK, Neuromuscular interactions between mivacurium and esmolol in rabbits. Anaesthesia. 1998 Feb;     [PubMed PMID: 9534636]


Bensky KP,Donahue-Spencer L,Hertz GE,Anderson MT,James R, The dose-related effects of bolus esmolol on heart rate and blood pressure following laryngoscopy and intubation. AANA journal. 2000 Oct     [PubMed PMID: 11759128]


Sheppard D,DiStefano S,Byrd RC,Eschenbacher WL,Bell V,Steck J,Laddu A, Effects of esmolol on airway function in patients with asthma. Journal of clinical pharmacology. 1986 Mar;     [PubMed PMID: 2870080]


Tao Y,Jingyi W,Xiaogan J,Weihua L,Xiaoju J, [Effect of esmolol on fluid responsiveness and hemodynamic parameters in patients with septic shock]. Zhonghua wei zhong bing ji jiu yi xue. 2015 Nov     [PubMed PMID: 27132454]


Barbier GH,Shettigar UR,Appunn DO, Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol. International journal of clinical pharmacology and therapeutics. 1995 Apr     [PubMed PMID: 7620691]


Litman RS,Zerngast BA, Cardiac arrest after esmolol administration: a review of acute beta-blocker toxicity. The Journal of the American Osteopathic Association. 1996 Oct     [PubMed PMID: 8936932]


Kapitein B,Biesmans RCG,van der Sijs H,de Wildt SN, Propylene Glycol-Related Delirium After Esmolol Infusion. The Annals of pharmacotherapy. 2014 Jul;     [PubMed PMID: 24687543]


Sun KO, Bronchospasm after esmolol and neostigmine. Anaesthesia and intensive care. 1993 Aug     [PubMed PMID: 8105719]


Rotella JA,Greene SL,Koutsogiannis Z,Graudins A,Hung Leang Y,Kuan K,Baxter H,Bourke E,Wong A, Treatment for beta-blocker poisoning: a systematic review. Clinical toxicology (Philadelphia, Pa.). 2020 Oct;     [PubMed PMID: 32310006]

Level 1 (high-level) evidence


Kirchhof P, Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines. Heart (British Cardiac Society). 2017 May     [PubMed PMID: 28077464]